SCHEMBL3775324

SCHEMBL3775324

CC(C)(C)OC(=O)N1CCC(Nc2nccc(C(F)(F)F)n2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 2/20 0.60
IDH2 P48735 1/20 0.60
HSD11B1 P28845 1/20 0.52
ALDH1A1 P00352 2/20 0.52
SYK P43405 2/20 0.51
NPC1 O15118 1/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ADORA2A P29274 1/20 0.48
GPR119 Q8TDV5 5/20 0.48
HDAC4 P56524 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
DNMT3A Q9Y6K1 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
CCNA2 P20248 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190733 0.85 ALDH1A1 (0.55) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL12367077 0.85 ALDH1A1 (0.55) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL14190850 0.84 ADORA2A (0.56) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL6151213 0.84 GRIN2B (0.51) IDH1IDH2GPR119
SCHEMBL14834214 0.84 HSD11B1 (0.51) IDH1IDH2HSD11B1HDAC8
SCHEMBL16538542 0.84 SYK (0.57) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL2121094 0.83 ALDH1A1 (0.57) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL3778502 0.83 ALDH1A1 (0.55) IDH1IDH2ALDH1A1SYKNPC1
SCHEMBL4062890 0.82 GPR119 (0.61) IDH1IDH2ALDH1A1NPC1MAPT
SCHEMBL27227572 0.82 CTSK (0.55) IDH1IDH2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
CN-101405284-A Pyrimidine, quinazoline, pteridine and derivatives HOFFMANN LA ROCHE (CH) 2009-04-08 CN disclosed
EP-2001867-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 IDH1 2178/4885IDH2 3095/4885HSD11B1 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.